{
    "clinical_study": {
        "@rank": "48777", 
        "arm_group": {
            "arm_group_label": "Oral Parathyroid Hormone (1-34)", 
            "arm_group_type": "Experimental", 
            "description": "Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)"
        }, 
        "brief_summary": {
            "textblock": "This is an observational, international, open label, pilot study to evaluate the safety,\n      tolerability and efficacy of an oral PTH (1-34) preparation produced by Entera Bio in adult\n      hypoparathyroid volunteers."
        }, 
        "brief_title": "A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypoparathyroidism", 
        "condition_browse": {
            "mesh_term": "Hypoparathyroidism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed diagnosis of primary hypoparathyroidism for more than 1 year.\n\n          -  Currently taking >1.0 grams of Calcium/day with a correlate alpha D3 dose.\n\n          -  25(OH)D levels \u2265 20 ng/ml.\n\n          -  Signed informed consent.\n\n          -  BMI 18 - 30 kg/m2, inclusive.\n\n          -  Full blood count should be within the reference range as per WHO criteria. Minor\n             abnormalities will be assessed by the Principle Investigator and after discussion\n             with sponsor patients may still be entered if these are felt to be of \"no clinical\n             importance\". Abnormalities due to hypoparathyroidism related are acceptable and will\n             not constitute exclusion.\n\n          -  Patients with significant liver function impairment (liver enzymes above x3 the upper\n             limit of normal range as per WHO criteria) will be excluded.\n\n          -  Subjects able to adhere to the visit schedule and protocol requirements.\n\n        Exclusion Criteria:\n\n          -  Haemoglobin <12 g/dL (females)/ <13gm/dL (males) [lower limit of reference range\n             12-15 & 13-17]\n\n          -  Impaired renal function\n\n          -  impaired liver function; ALT >38 international units per liter (IU/L), or ALP>125\n             IU/L\n\n          -  Significant drug or alcohol abuse as assessed by the Principal Investigator\n\n          -  Allergy to soy bean products\n\n          -  Presence of kidney or urinary tract stones\n\n          -  Concurrent therapy that, in the Investigator's opinion, would interfere with the\n             evaluation of the safety or efficacy of the study medication.\n\n          -  Treatment with any investigational product within the last 30 days, enrollment or\n             intention to enroll in any active study involving the use of investigational devices\n             or drugs.\n\n          -  Presence of any other condition or circumstance that, in the judgment of the\n             Investigator, might increase the risk to the patient or decrease the chance of\n             obtaining satisfactory data to achieve the objectives of the study.\n\n          -  Active infections\n\n          -  Pregnancy or suspected pregnancy. Female subjects must have a negative serum\n             pregnancy test at screening and be willing and able to use a medically acceptable\n             method of birth control (reliable use of oral contraceptive, non-hormonal\n             intrauterine device with condom, or diaphragm with condom, or condom with spermicide)\n             from the screening visit through the study termination visit or declare that they are\n             abstaining from sexual intercourse from the screening visit through the study\n             termination visit or are surgically sterile (have undergone bilateral tubal ligation,\n             bilateral oophorectomy, or hysterectomy) or post-menopausal. Postmenopausal women are\n             defined as women with menstruation cessation for 12 consecutive months prior to\n             signing of the informed consent form."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152228", 
            "org_study_id": "ENT-03-2014"
        }, 
        "intervention": {
            "arm_group_label": "Oral Parathyroid Hormone (1-34)", 
            "description": "Oral administration", 
            "intervention_name": "EnteraBio's Oral Parathyroid Hormone (1-34)", 
            "intervention_type": "Drug", 
            "other_name": "Teriparatide"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Teriparatide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "s_ish_shalom@rambam.health.gov.il", 
                "last_name": "Sophia Ish Shalom, MD", 
                "phone": "972-4-8542828"
            }, 
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel", 
                    "zip": "35152"
                }, 
                "name": "Lin Medical Center"
            }, 
            "investigator": {
                "last_name": "Sophia Ish Shalom, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism", 
        "overall_contact": {
            "email": "s_ish_shalom@rambam.health.gov.il", 
            "last_name": "Sophia Ish Shalom, MD", 
            "phone": "972-4-8542828"
        }, 
        "overall_official": {
            "affiliation": "Rambam Health Care Campus", 
            "last_name": "Sophia Ish Shalom, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Israel: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "safety will be measured by monitoring and recording adverse events related to hyper- and hypocalcemia", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 17 weeks"
            }, 
            {
                "measure": "Reduction in use of exogenous calcium supplement and/or alpha D3  supplement", 
                "safety_issue": "No", 
                "time_frame": "up to 17 weeks"
            }, 
            {
                "measure": "Tolerability- The rate of discontinuation of patients' participation in the study due to adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 17 weeks"
            }, 
            {
                "measure": "Plasma calcium levels", 
                "safety_issue": "No", 
                "time_frame": "at baseline and 60 minutes post-dose"
            }, 
            {
                "description": "To study the pharmacokinetic profile of PTH absorption", 
                "measure": "Peak Plasma Concentration (Cmax)of treatment", 
                "safety_issue": "No", 
                "time_frame": "at baseline and time-points 10, 15, 20, 30, 45, 60, 90, and 180 post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152228"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Compliance to treatment defined as proportion taking >80% study medication (good), 60-80% (satisfactory) and <60% (poor)", 
                "measure": "The volunteers' compliance to treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 17 weeks"
            }, 
            {
                "description": "Patients will report a Quality Of Life (QOL) review", 
                "measure": "Patient quality of life", 
                "safety_issue": "No", 
                "time_frame": "up to 17 weeks"
            }
        ], 
        "source": "Entera Bio Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Entera Bio Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}